BeOne Medicines Ltd.(ONC)Earnings, Financials & Key Ratios

ONC•NASDAQ

$308.96

9.4× P/E·Price updated Jul 7, 2026

SectorHealthcare IndustryPharmaceuticals Sub-IndustryCommercial Specialty Biopharma

AboutBeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.Show more

Revenue$5.34B+40.2%
EBITDA$589M+248.5%
Net Income$287M+144.5%
EPS (Diluted)32.89+637.4%
Gross Margin87.49%+3.6%
EBITDA Margin11.02%+205.9%
Operating Margin8.37%+156.1%
Net Margin5.37%+131.7%
ROE7.46%+139.7%

ONC Price & Volume

BeOne Medicines Ltd. (ONC) stock price & volume — 10-year historical chart

Loading chart...

Commercial Scaling Drives Sustained Oncology Revenue Growth

Investment Thesis • Updated 2026Q1

VerdictPositive: The company has achieved a critical inflection point with $227.4 million in net income for 2026Q1

Growth:Expanding

Profitability:Moderate

Financial:Healthy

Cash Flow:Improving

Primary Risk:Geopolitical and Regulatory Exposure

Key Thesis Takeaways

BeOne Medicines has successfully transitioned from a cash-burning R&D entity to a profitable commercial enterprise, evidenced by revenue growth to $1.5 billion in 2026Q1.
While the firm maintains a robust $4.8 billion cash position to support its $541.2 million quarterly R&D commitment, investors should monitor the impact of significant stock-based compensation, which reached $757.1 million in 2025Q4, on long-term earnings quality.
The company's ability to maintain its 89.0% gross margin while scaling global operations suggests a sustainable competitive advantage in the oncology sector.

Verdict Logic

demonstrating that its commercial portfolio can now effectively fund its ongoing $541.2 million quarterly R&D investment.

ONC Growth Metrics

BeOne Medicines Ltd. (ONC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years89.78%

5 Years76.85%

3 Years55.69%

TTM37.44%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM230.75%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM1349.33%

Return on Capital

10 Years-31.93%

5 Years-17.66%

3 Years-11%

Last Year8.88%

ONC Recent Earnings

BeOne Medicines Ltd. (ONC) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 5/12 qtrs (63%)●Beat Revenue 3/12 qtrs (50%)

Q2 2026Latest

May 6, 2026

Metric

Actual

Est

EPS

$1.96+168.5%

$0.73

Rev

$1.5B+5.4%

$1.4B

Q1 2026

Feb 26, 2026

Metric

Actual

Est

EPS

$0.58-63.7%

$1.60

Rev

$1.5B+2.2%

$1.5B

Q4 2025

Nov 6, 2025

Metric

Actual

Est

EPS

$1.09+51.4%

$0.72

Rev

$1.4B-2.7%

$1.5B

Q3 2025

Aug 6, 2025

Metric

Actual

Est

EPS

$0.84+75.0%

$0.48

Rev

$1.3B-8.8%

$1.4B

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	May 6, 2026	$1.96vs $0.73+168.5%	$1.5Bvs $1.4B+5.4%
Q1 2026	Feb 26, 2026	$0.58vs $1.60-63.7%	$1.5Bvs $1.5B+2.2%
Q4 2025	Nov 6, 2025	$1.09vs $0.72+51.4%	$1.4Bvs $1.5B-2.7%
Q3 2025	Aug 6, 2025	$0.84vs $0.48+75.0%	$1.3Bvs $1.4B-8.8%

Based on last 12 quarters of dataView full earnings history →

Latest ONC News

Recent stock market news and headlines for BeOne Medicines Ltd. (ONC)

Business Wire·Jun 30, 2026

BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK inhibitor BRUKINSA® (zanubrutinib) plus rituximab versus bendamustine plus rituximab (BR) in adult patients with previously untreated mantle cell lymphoma (MCL). MANGROVE is the first Phase 3, global, randomized trial to evaluate a BTK inhibito.

Peers Comparison

Key metrics vs top competitors for BeOne Medicines Ltd. (ONC)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
ONCBeOne Medicines Ltd.Current	$308.96	$33.01B	9.39	40.23%	5.37%	7.46%	—
ZYMEZymeworks Inc.	$26.72	$1.97B	-24.74	38.87%	-126.33%	-0.25%	—
RCUSArcus Biosciences, Inc.	$30.25	$3.05B	-9.19	-4.26%	-156.36%	-68.97%	—
TGTXTG Therapeutics, Inc.	$53.52	$8.19B	19.32	87.32%	65.95%	87.36%	—
KYMRKymera Therapeutics, Inc.	$119.24	$9.74B	-32.31	-16.72%	-612.17%	-25.02%	—
MGNXMacroGenics, Inc.	$4.75	$301.92M	-4.03	0.78%	-44.79%	-147.8%	—

Compare ONC vs Peers

BeOne Medicines Ltd. (ONC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ZYME

Most directly comparable listed peer for ONC.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare ONC against a more recognizable public peer.

Peer Set

Compare Top 5

vs ZYME, RCUS, TGTX, KYMR

ONC SEC Filings & Documents

BeOne Medicines Ltd. (ONC) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 6, 2026·SEC

Material company update

Apr 14, 2026·SEC

Material company update

Feb 26, 2026·SEC

10-K Annual Reports

FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 27, 2025·SEC

10-Q Quarterly Reports

FY 2026

May 6, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 6, 2025·SEC

Get notified when ONC posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

ONC Frequently Asked Questions

BeOne Medicines Ltd. (ONC) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is BeOne Medicines Ltd.'s revenue?

BeOne Medicines Ltd. (ONC) reported $5.74B in revenue for fiscal year 2025. This represents a 51382% increase from $11.1M in 2013.

How fast is BeOne Medicines Ltd. growing?

BeOne Medicines Ltd. (ONC) grew revenue by 40.2% over the past year. This is strong growth.

Is ONC profitable?

Yes, BeOne Medicines Ltd. (ONC) is profitable, generating $513.0M in net income for fiscal year 2025 (5.4% net margin).

Dividend & Returns

What is ONC's return on equity?

BeOne Medicines Ltd. (ONC) has a return on equity (ROE) of 7.5%. This is below average, suggesting room for improvement.

What is BeOne Medicines Ltd.'s free cash flow?

BeOne Medicines Ltd. (ONC) generated $846.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in ONC back in 2013?

Total return calculator · dividends reinvested · 13+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

May 6, 2026

$1.96vs $0.73+168.5%

$1.5Bvs $1.4B+5.4%

Q1 2026

Feb 26, 2026

$0.58vs $1.60-63.7%

$1.5Bvs $1.5B+2.2%

Q4 2025

Nov 6, 2025

$1.09vs $0.72+51.4%

$1.4Bvs $1.5B-2.7%

Q3 2025

Aug 6, 2025

$0.84vs $0.48+75.0%

$1.3Bvs $1.4B-8.8%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

ONCBeOne Medicines Ltd.Current

$308.96

$33.01B

9.39

40.23%

5.37%

7.46%

—

ZYMEZymeworks Inc.

$26.72

$1.97B

-24.74

38.87%

-126.33%

-0.25%

—

RCUSArcus Biosciences, Inc.

$30.25

$3.05B

-9.19

-4.26%

-156.36%

-68.97%

—

TGTXTG Therapeutics, Inc.

$53.52

$8.19B

19.32

87.32%

65.95%

87.36%

—

KYMRKymera Therapeutics, Inc.

$119.24

$9.74B

-32.31

-16.72%

-612.17%

-25.02%

—

MGNXMacroGenics, Inc.

$4.75

$301.92M

-4.03

0.78%

-44.79%

-147.8%

—